UNLABELLED: In the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) study, women with incident clinical fractures reported significant declines in health-related quality of life (HRQoL). The largest declines were observed when the assessment was <3 months post fracture. The largest impact of incident clinical fractures was on physical function, and that of incident clinical vertebral fractures was on back pain. INTRODUCTION: In the FREEDOM trial, denosumab significantly reduced the risk of new vertebral, hip, and nonvertebral fractures. We evaluated the effect of denosumab on HRQoL and the association between incident clinical fractures and HRQoL. METHODS: The FREEDOM trial enrolled 7,868 women aged 60-90 years with a total hip and/or lumbar spine BMD T-score <-2.5 and not <-4.0 at either site. Women were randomized to receive denosumab 60 mg or placebo every 6 months, in addition to daily calcium and vitamin D. HRQoL was assessed with the Osteoporosis Assessment Questionnaire-Short Version (OPAQ-SV) at baseline and every 6 months for 36 months. The OPAQ-SV assesses physical function, emotional status, and back pain. Higher scores indicate better health status. RESULTS: No statistically significant differences in mean change in HRQoL from baseline to end of study were found when comparing treatment groups. Compared with women without any incident fractures during the study, women with incident clinical fractures reported significant declines in physical function (-4.0 vs. -0.5) and emotional status (-5.0 vs. -0.8) at month 36 (P < 0.001 for both). Importantly, time-dependent covariate analyses demonstrated that the largest declines were observed when the assessment was <3 months post fracture. The largest impact of incident clinical fractures was on physical function, and that of incident clinical vertebral fractures was on back pain. CONCLUSIONS: These findings not only demonstrate that incident clinical fractures impact HRQoL but also contribute new information regarding the impact of these fracture events on HRQoL over time.
RCT Entities:
UNLABELLED: In the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) study, women with incident clinical fractures reported significant declines in health-related quality of life (HRQoL). The largest declines were observed when the assessment was <3 months post fracture. The largest impact of incident clinical fractures was on physical function, and that of incident clinical vertebral fractures was on back pain. INTRODUCTION: In the FREEDOM trial, denosumab significantly reduced the risk of new vertebral, hip, and nonvertebral fractures. We evaluated the effect of denosumab on HRQoL and the association between incident clinical fractures and HRQoL. METHODS: The FREEDOM trial enrolled 7,868 women aged 60-90 years with a total hip and/or lumbar spine BMD T-score <-2.5 and not <-4.0 at either site. Women were randomized to receive denosumab 60 mg or placebo every 6 months, in addition to daily calcium and vitamin D. HRQoL was assessed with the Osteoporosis Assessment Questionnaire-Short Version (OPAQ-SV) at baseline and every 6 months for 36 months. The OPAQ-SV assesses physical function, emotional status, and back pain. Higher scores indicate better health status. RESULTS: No statistically significant differences in mean change in HRQoL from baseline to end of study were found when comparing treatment groups. Compared with women without any incident fractures during the study, women with incident clinical fractures reported significant declines in physical function (-4.0 vs. -0.5) and emotional status (-5.0 vs. -0.8) at month 36 (P < 0.001 for both). Importantly, time-dependent covariate analyses demonstrated that the largest declines were observed when the assessment was <3 months post fracture. The largest impact of incident clinical fractures was on physical function, and that of incident clinical vertebral fractures was on back pain. CONCLUSIONS: These findings not only demonstrate that incident clinical fractures impact HRQoL but also contribute new information regarding the impact of these fracture events on HRQoL over time.
Authors: Susan K Brenneman; Elizabeth Barrett-Connor; Shiva Sajjan; Leona E Markson; Ethel S Siris Journal: J Bone Miner Res Date: 2006-06 Impact factor: 6.741
Authors: J Lawrence Marsh; Todd McKinley; Douglas Dirschl; Andrew Pick; Geoffrey Haft; Donald D Anderson; Thomas Brown Journal: J Orthop Trauma Date: 2010-08 Impact factor: 2.512
Authors: Steven R Cummings; Javier San Martin; Michael R McClung; Ethel S Siris; Richard Eastell; Ian R Reid; Pierre Delmas; Holly B Zoog; Matt Austin; Andrea Wang; Stepan Kutilek; Silvano Adami; Jose Zanchetta; Cesar Libanati; Suresh Siddhanti; Claus Christiansen Journal: N Engl J Med Date: 2009-08-11 Impact factor: 91.245
Authors: Fausto Salaffi; Marco Amedeo Cimmino; Nazzarena Malavolta; Marina Carotti; Luigi Di Matteo; Pietro Scendoni; Walter Grassi Journal: J Rheumatol Date: 2007-05-15 Impact factor: 4.666
Authors: Alexandra Papaioannou; Nancy Santesso; Suzanne N Morin; Sidney Feldman; Jonathan D Adachi; Richard Crilly; Lora M Giangregorio; Susan Jaglal; Robert G Josse; Sharon Kaasalainen; Paul Katz; Andrea Moser; Laura Pickard; Hope Weiler; Susan Whiting; Carly J Skidmore; Angela M Cheung Journal: CMAJ Date: 2015-09-14 Impact factor: 8.262
Authors: F Borgström; G Olafsson; O Ström; J B Tillman; D Wardlaw; S Boonen; C Miltenburger Journal: Osteoporos Int Date: 2013-04-27 Impact factor: 4.507
Authors: Sarah Davis; Emma Simpson; Jean Hamilton; Marrissa Martyn-St James; Andrew Rawdin; Ruth Wong; Edward Goka; Neil Gittoes; Peter Selby Journal: Health Technol Assess Date: 2020-06 Impact factor: 4.014
Authors: B Buecking; J Struewer; A Waldermann; K Horstmann; N Schubert; M Balzer-Geldsetzer; R Dodel; K Bohl; S Ruchholtz; C Bliemel Journal: Osteoporos Int Date: 2013-06-20 Impact factor: 4.507
Authors: Östen Ljunggren; Annabel Barrett; Ivaylo Stoykov; Bente L Langdahl; Willem F Lems; J Bernard Walsh; Astrid Fahrleitner-Pammer; Gerald Rajzbaum; Franz Jakob; Dimitrios Karras; Fernando Marin Journal: BMC Musculoskelet Disord Date: 2013-08-22 Impact factor: 2.362